David Jawahar, MD
Pulmonary Disease · Dover, DENPI 1306828330
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 437 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by AstraZeneca at 27.4% of the total. 2025 is the largest year on record at $2,267, 3.4 times the $673 reported in 2019.
Across 437 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$715
- Sanofi$533
- Boehringer Ingelheim$460
- Genentech USA, Inc.$329
- plus $3K from 31 others
What the payments were for
- Food & beverage$8,98098%
- Education$2002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 104 | $2,519 |
| GSK | 110 | $1,443 |
| Regeneron Healthcare Solutions, Inc. | 21 | $715 |
| Sanofi | 24 | $533 |
| Boehringer Ingelheim | 27 | $460 |
| Genentech USA, Inc. | 16 | $329 |
| Mallinckrodt Hospital Products Inc. | 11 | $320 |
| Jazz Pharmaceuticals Inc. | 14 | $276 |
| Pulmonx Corporation | 9 | $265 |
| Mylan Specialty L.p. | 11 | $265 |
| Novartis | 12 | $216 |
| Actelion Pharmaceuticals US, Inc. | 8 | $194 |
| Insmed, Inc. | 7 | $149 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $147 |
| Bayer | 2 | $142 |
| Viatris Specialty LLC | 5 | $129 |
| Philips North America LLC | 6 | $105 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| Grifols USA, LLC | 4 | $84 |
| Harmony Biosciences LLC | 3 | $74 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $73 |
| Resmed Corp | 4 | $65 |
| Amgen | 4 | $65 |
| Verona Pharma, Inc. | 3 | $61 |
| Merck | 3 | $54 |
| Axsome Therapeutics, Inc. | 3 | $52 |
| Covis Pharma GmbH | 2 | $52 |
| Greer Laboratories, Inc. | 2 | $47 |
| Electromed, Inc. | 2 | $46 |
| Tactile Systems Technology Inc | 2 | $40 |
| United Therapeutics Corporation | 2 | $38 |
| ANI Pharmaceuticals, Inc. | 1 | $34 |
| Lilly USA, LLC | 1 | $29 |
| AbbVie | 1 | $24 |
| CMP Pharma, Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,180 in reported general payments places this provider in the 80th percentile of 39 pulmonary disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 830 | $1,032,304 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 182 | $192,841 |
| Fasenra PenBenralizumab | 23 | $131,621 |
| Dupixent PenDupilumab | 34 | $124,721 |
| Ambrisentan | 19 | $116,829 |
| XolairOmalizumab | 20 | $95,228 |
| Breo ElliptaFluticasone/Vilanterol | 115 | $85,235 |
| Dupixent SyringeDupilumab | 22 | $79,779 |
| TezspireTezepelumab-Ekko | 11 | $50,030 |
| Pirfenidone | 16 | $44,820 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 52 | $36,384 |
| Spiriva RespimatTiotropium Bromide | 25 | $33,521 |
| Spiriva HandihalerTiotropium Bromide | 28 | $27,293 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 687 | $21,987 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 31 | $21,762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,443 | $1,170,5601,038 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $2,519 | $255,321232 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $460 | $55,28356 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 39 pulmonary disease providers in Delaware.
Other pulmonary disease in Dover
- Margarita GianniosisDover$4K
- Alejandro Sardi-FreitezDover$3K
- Brian WalshDover$1K
- Maria AzharDover$0
- Victor BanzonLewes$300K
- Albert RizzoNewark$162K
- Michel SamahaMilford$94K
- Haroon RajaNewark$44K
- Ismael MatusNewark$27K
- Vikas BatraLewes$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.